国家: 新西兰
语言: 英文
来源: Medsafe (Medicines Safety Authority)
Idarubicin hydrochloride 20mg
Pfizer New Zealand Limited
Idarubicin hydrochloride 20 mg
20 mg
Powder for injection
Active: Idarubicin hydrochloride 20mg Excipient: Lactose monohydrate
Vial, glass, (not marketed), 1 dose unit
Prescription
Prescription
Olon SpA
Package - Contents - Shelf Life: Vial, glass, - 1 dose units - 36 months from date of manufacture stored at or below 25°C 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze)
1990-01-17
ZAVEDOS ® 1 ZAVEDOS ® _Idarubicin hydrochloride _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET PLEASE READ THIS LEAFLET CAREFULLY BEFORE TREATMENT WITH ZAVEDOS. This leaflet answers some common questions about this medicine. It does not contain all the available information. It does not take the place of talking to your doctor. All medicines have risks and benefits. Your doctor has weighed the risks of treating you with ZAVEDOS against the benefits they expect it will have for you. ASK YOUR DOCTOR OR PHARMACIST, IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE. PLEASE KEEP THIS LEAFLET. You may need to read it again. WHAT ZAVEDOS IS USED FOR ZAVEDOS is used to treat: • a type of leukaemia in adults known as AML (acute myelogenous leukaemia). • advanced breast cancer. It works by stopping cancer cells from growing and multiplying. ZAVEDOS may be used alone or in combination with other chemotherapy. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY ZAVEDOS HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another reason. ZAVEDOS is only available with a doctor's prescription. It is not addictive. BEFORE TREATMENT WITH ZAVEDOS _WHEN ZAVEDOS MUST NOT _ _BE USED _ DO NOT TAKE ZAVEDOS IF YOU HAVE AN ALLERGY TO: • any medicine containing idarubicin hydrochloride • other similar medicines for cancer, e.g., daunorubicin, doxorubicin, epirubicin, mitozantrone • any of the ingredients listed at the end of this leaflet Symptoms of an allergic reaction to ZAVEDOS may include: • shortness of breath, wheezing or difficulty breathing • swelling of the face, lips, tongue or other parts of the body • rash, itching or hives on the skin DO NOT TAKE THE MEDICINE IF YOU HAVE: • severe kidney problems • severe liver problems • severe heart problems including heart failure, abnormal heartbeat or a recent heart attack • a severe infection, with signs such as fever, severe chills, sore throat or mouth ulcers • reduced number of red or white blood cells or platelets • previously 阅读完整的文件
Version: pfdzavea11121 Supersedes: pfdzavea11220 Page 1 of 14 NEW ZEALAND DATA SHEET 1. PRODUCT NAME ZAVEDOS ® 5 mg, 10 mg Powder for Injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of ZAVEDOS Powder for Injection contains 5 mg or 10 mg of idarubicin hydrochloride. For the full list of excipients, see Section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Powder for Injection. ZAVEDOS 5 mg and 10 mg Powder for Injection is a sterile, orange-red lyophilised powder. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS ZAVEDOS is an antimitotic and cytotoxic agent. It is indicated for use in acute myelogenous leukaemia (AML), in adults for remission induction in untreated patients, or for remission induction in relapsed or refractory patients. ZAVEDOS is also an effective agent for use in the second line treatment of advanced breast cancer either as a single agent or in a combination regimen. 4.2 DOSE AND METHOD OF ADMINISTRATION ZAVEDOS treatment should be initiated or overseen by personnel experienced in chemotherapy. Dosage is usually calculated on the basis of body surface area. DOSE For induction therapy in adult patients with AML, the following dose schedule is recommended: ZAVEDOS 12 mg/m 2 daily for 3 days by slow (10-15 min) intravenous injection in combination with cytarabine 100 mg/m 2 daily given by continuous infusion for seven days. In patients with unequivocal evidence of leukaemia after the first induction course, a second course may be administered. Administration of the second course should be delayed in patients who experienced severe mucositis, until recovery from this toxicity has occurred, and a dose reduction of 25% is recommended. Version: pfdzavea11121 Supersedes: pfdzavea11220 Page 2 of 14 For reconstitution of the freeze-dried formulation, see Method of administration below. Also refer to Section 6.4 Special precautions for storage for storage conditions for the unreconstituted Powder for injection and the reconstituted solution. All dosage schedules should take into accou 阅读完整的文件